Physician profile
Minghua He
NPI 1023072071
$2,364.67
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $330 · 2021: $512 · 2022: $349 · 2023: $414 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $422.66 | 2019-2024 | |
| Tris Pharma INC | $268.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.97 | 2019-2022 | |
| Corium, LLC | $210.83 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $187.36 | 2019-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Adlon Therapeutics L.P. | $150.70 | 2019-2021 | |
| Sanofi Pasteur INC. | $141.10 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $115.65 | 2023-2024 | Qelbree |
| Sobi, INC | $110.21 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $104.55 | 2019-2022 | |
| Kaleo, INC. | $100.60 | 2019-2022 | |
| Genentech USA, INC. | $98.83 | 2019-2022 | |
| Neos Therapeutics, LP | $82.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.78 | 2020-2023 | Bexsero, Pediarix |
| Sanofi-Aventis U.S. LLC | $35.17 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $27.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minghua He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.